Misplaced Pages

This is an old revision of this page, as edited by Beetstra (talk | contribs) at 11:21, 24 October 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'DrugBank', 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Anecortave acetate

Clinical data
AHFS/Drugs.com	International Drug Names
Pregnancy category	?
Routes of administration	intravitreal depot injection
ATC code	S01LA02 (WHO)
Legal status
Legal status	Schedule 4 (Aust)
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Elimination half-life	?
Excretion	?
Identifiers
IUPAC name phenanthren-17-yl]- 2-oxo-ethyl] acetate
PubChem CID	111332
ChemSpider	99892
UNII	Y0PC411K4T
CompTox Dashboard (EPA)	DTXSID5046805
ECHA InfoCard	100.028.920
Chemical and physical data
Formula	C23H30O5
Molar mass	386.48 g·mol
3D model (JSmol)	Interactive image
SMILES O=C(OCC(=O)1(O)CC24/C(=C\C12C)3(/C(=C\C(=O)CC3)CC4)C)C
InChI InChI=1S/C23H30O5/c1-14(24)28-13-20(26)23(27)11-8-19-17-5-4-15-12-16(25)6-9-21(15,2)18(17)7-10-22(19,23)3/h7,12,17,19,27H,4-6,8-11,13H2,1-3H3/t17-,19+,21+,22+,23+/m1/s1 Key:YUWPMEXLKGOSBF-GACAOOTBSA-N
(verify)

Anecortave (rINN) (/ænəˈkɔːrteɪv/) is a novel angiogenesis inhibitor used in the treatment of the exudative (wet) form of age-related macular degeneration. Although based on a steroid nucleus, it possesses little glucocorticoid activity. It will be marketed by Alcon as anecortave acetate for depot suspension under the trade name Retaane.

Synthesis

Anecortave can be synthesized from a 17-oxosteroid:

References

1. J.G. Reid, T. Debiak-Krook (1990). "Corticoids from 17-oxosteroids". Tetrahedron Lett. 31: 3669. doi:10.1016/S0040-4039(00)97440-9.

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Ill-formatted IPAc-en transclusions
• Pharmacology stubs
• Angiogenesis inhibitors
• Steroids